Medicine and Dentistry
Clinical Trial
100%
Malignant Neoplasm
82%
Oncology
64%
Radiation Therapy
47%
Randomized Clinical Trial
34%
Diseases
32%
Overall Survival
31%
Solid Malignant Neoplasm
29%
Pancreas Cancer
26%
Local Therapy
22%
Stereotactic Body Radiation Therapy
20%
Odds Ratio
18%
Oropharynx Carcinoma
18%
Head and Neck Cancer
18%
Radiomics
17%
Hepatocellular Carcinoma
17%
Liver Transplantation
17%
Ewing Sarcoma
17%
Group Trial
17%
Systemic Therapy
14%
Logistic Regression Analysis
14%
Randomized Controlled Trial
12%
Patient-Reported Outcome
12%
Lung Cancer
12%
Cancer
11%
Subgroup Analysis
11%
Kaplan Meier Method
10%
Breast Cancer
10%
Xerostomia
9%
Neoplasm
9%
Clinical Oncology
9%
Biological Marker
9%
Wart Virus
9%
Recurrent Disease
9%
positron emission tomographic scan
8%
English (Language)
8%
Treatment Effect
8%
Nutrition
8%
Racial Disparity
8%
Adaptive Radiotherapy
8%
Oropharynx Squamous Cell Carcinoma
8%
Magnetic Resonance Imaging of Head
8%
Neck
8%
Pancoast Tumor
8%
Radiation Oncology
8%
Ethnic Disparity
8%
Magnetic Resonance Imaging of Neck
8%
Thorax Tumor
8%
Progression Free Survival
8%
Systematic Review
8%
Keyphrases
Cancer Clinical Trials
78%
Oncology Trials
38%
Overall Survival
35%
Age Disparity
26%
Local Therapy
22%
Cooperative Group
21%
Confidence Interval
20%
Clinical Trial Participant
20%
Stereotactic Body Radiation Therapy
17%
Suboptimal Control
17%
Ewing Sarcoma
17%
Cooperative Group Trial
16%
Metastatic Tumor
15%
Oncologic
15%
Randomized Clinical Trial
14%
Multivariable
14%
Industry-funded
14%
Oncology Clinical Trials
11%
In Cancer
10%
Site of Disease
10%
Radiation Therapy
10%
Enrollment Criteria
10%
Randomized Controlled Trial
10%
Performance Status
9%
Hepatocellular Carcinoma
9%
Industry Funding
9%
Treatment Effect
9%
Exclusion Criteria
9%
Oncological Outcomes
9%
Trial Results
9%
Clinical Trials
8%
Proportional Hazards Model
8%
Confounding
8%
Serious Adverse Events
8%
Post-liver Transplantation
8%
Treatment Adaptation
8%
Lymph Node Involvement
8%
Non-publication
8%
Clinical Meaning
8%
Clinical Progression
8%
Resectable Pancreatic Cancer
8%
Treatment Facilities
8%
Post-progression Therapy
8%
Medical Writer
8%
Nasopharyngeal Carcinoma
8%
Delivered Dose
8%
Local Control
8%
Pancreatic Cancer
8%
Therapy Discontinuation
8%
Racial Disparities
8%
